Company news

AIM ImmunoTech Inc. news in 2026

AIM ImmunoTech Inc.'s news releases, calls and decks from 2026, newest first.

View company

AIM ImmunoTech Highlights Ampligen® Opportunity to Potentially Extend Benefits of RAS-Targeted Therapies in Pancreatic Cancer

November 5, 2026

AIM ImmunoTech Significantly Expands Ampligen Global Patent Estate with Long COVID Protection across Europe and the United Kingdom Through 2041

September 3, 2026

AIM ImmunoTech Reports Second Quarter 2026 Financial Results and Highlights Significant Operational Execution Advancing Ampligen(R) Toward Planned Phase 3 Development in Pancreatic Cancer

August 11, 2026

AIM ImmunoTech Reports Second Quarter 2026 Financial Results and Highlights Significant Operational Execution Advancing Ampligen® Toward Planned Phase 3 Development in Pancreatic Cancer

August 10, 2026

Ahead of Schedule on 'Last Dose' DURIPANC Critical Clinical Inflection Point

August 3, 2026

AIM ImmunoTech Announces Release of New CEO Corner Segment Highlighting Growing Momentum Across Pancreatic Cancer Program

July 7, 2026

AIM ImmunoTech Accelerates Toward Potential Pivotal Pancreatic Cancer Program as Ampligen Continues to Advance Through Key Clinical Milestones

June 24, 2026

AIM ImmunoTech to Present in the Webull Corporate Connect Webinar Series

June 22, 2026

AIM ImmunoTech Achieves Clinical Milestone as Final Subject Receives First Dose in Phase 2 DURIPANC Study in Metastatic Pancreatic Cancer

June 18, 2026

AIM ImmunoTech Regains NYSE American Compliance, Company Resolves Stockholder Equity Deficiency

June 15, 2026

AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market under NYSE American Rules

June 9, 2026

AIM ImmunoTech Reports Positive Mid-Year Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer

June 8, 2026

AIM ImmunoTech Completes Phase 2 DURIPANC Enrollment Milestone Ahead of Schedule, Advancing Ampligen Toward Critical Pancreatic Cancer Clinical Milestones

June 1, 2026

AIM ImmunoTech Announces Emerging Ebola Opportunity for Ampligen Amid Escalating Global Health Concerns and WHO Emergency Declaration

May 27, 2026

AIM ImmunoTech Announces $2.4 Million Financing, Including Concurrent Registered Direct Offering and Private Placement

May 20, 2026

AIM ImmunoTech Announces Significant Increase in Stockholder Equity and Extension of Promissory Note Maturity Date to June 2027, Enhancing Financial Flexibility and Supporting Strategic Clinical Priorities

May 19, 2026

AIM ImmunoTech, Inc. Announces Exercise of Warrants for Approx. $4.2 Million in Gross Proceeds

May 8, 2026

AIM ImmunoTech Announces 50% Objective Response Rate (ORR) in UPMC Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential

May 7, 2026

AIM ImmunoTech Enters Pivotal Value Inflection Phase with Planned Phase 3 Study of Ampligen® in Pancreatic Cancer, Backed by Positive Clinical Signals, Orphan Drug Status, and Global IP

April 16, 2026

AIM ImmunoTech Provides Routine Update on Annual Filings

April 13, 2026

AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event

April 9, 2026

AIM ImmunoTech Announces Final Approval of Novel Cancer Therapy Patent in Japan Combining Ampligen with Checkpoint Inhibitors

March 18, 2026

AIM ImmunoTech Announces Closing of its Rights Offering

March 5, 2026

AIM ImmunoTech Announces Expiration and Preliminary Results of its Rights Offering for Aggregate Gross Proceeds of $1.8 Million

March 4, 2026

AIM ImmunoTech Signs Agreement for Planning of a Proposed Phase 3 Clinical Trial of Ampligen in the Treatment of Late-Stage Pancreatic Cancer

March 2, 2026

AIM ImmunoTech Reminds Stockholders of March 3, 2026 Expiration Date and Updates Terms of Previously Announced Rights Offering

February 27, 2026

AIM ImmunoTech Announces Extension of Subscription Period of its Previously Announced Rights Offering to March 3, 2026

February 25, 2026

AIM ImmunoTech Announces Planned Milestones in the Ongoing Phase 2 Trial of Ampligen and AstraZeneca’s Durvalumab in the Treatment of Metastatic Pancreatic Cancer

February 23, 2026

CORRECTION: AIM ImmunoTech Announces Commencement of Rights Offering

February 12, 2026

AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event

February 12, 2026

AIM ImmunoTech Announces Commencement of Rights Offering

February 11, 2026

AIM ImmunoTech to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

February 6, 2026

AIM ImmunoTech Reports Positive Year-End Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer

February 5, 2026

AIM ImmunoTech Announces Changes to Key Dates and Terms Related to Announced Rights Offering

January 27, 2026

AIM ImmunoTech Announces Key Dates and Terms Related to Announced Rights Offering

January 23, 2026

Decks in 2026